drugset / Trial / NCT00005093

Gemcitabine With or Without CI-994 in Treating Patients With Advanced Non-small Cell Lung Cancer

NCT00005093 ↗

Phase 3 Completed Pfizer
RandomizedTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether gemcitabine plus CI-994 is more effective than gemcitabine alone for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of gemcitabine with or without CI-994 in treating patients who have advanced non-small cell lung cancer.

Timeline

Start
1999-12
Primary completion
—
Completion
2001-05

Drugs

EvaluationDrugModalityDoseRoute
Subject tacedinaline Small molecule — Oral
Background Gemcitabine Small molecule — Intravenous

Indications